News - Biotechnology
Regenerative medicine industry poised for continued growth

Regenerative medicine, cell and gene therapy, is poised for continued expansion in 2020, after the latest global industry briefing reveals another year of significant growth, and total global financings the second highest yet.
Released at Biotech Showcase last week, the Alliance for Regenerative Medicine (ARM)’s State of the Industry presentation showed the US$9.8B of total global financing in 2019 was attributed to gene-based therapies, cell therapies, and tissue engineering.
Financing remains strong across venture capital and partnerships, with M&A activity showcasing large and middle cap pharma’s interest in the cell and gene therapy space.
The pipeline is robust, with several next-generation technologies entering the clinic, and an increase in clinical trials for indications with large patient populations. As at the end of 2019, there were a recorded 1,066 clinical trials underway, with 58% of phase I trials in gene-modified cell therapies.
Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.
Considerable effort and progress in addressing various manufacturing challenges are being made, with in-house manufacturing capabilities becoming a strategic priority, companies investing in manufacturing earlier in the development process, and CMOs becoming attractive acquisition targets.
AusBiotech is a member of ARM, an international community of over 350 small and large companies, non-profit research institutions, patient organisations, and other sector stakeholders dedicated to realising the promise of regenerative medicine for patients around the world.
Enhance employer branding and boost thought leadership in the industry to attract and retain quality employees. Health Industry Hub is the only one-stop-hub connecting your organisation to Australia’s Pharma, MedTech, and Biotech industry professionals. Get started with our unique media solutions.
Leadership & Management
David Henderson appointed Takeda Oceania Country Head
David Henderson has been appointed Country Head for Takeda Oceania, succeeding Dave Pearce, as the pharmaceutical company continues to reshape […]
MoreNews - Pharmaceuticals
GBMA puts medicine shortages on the table as strategic agreement talks begin
As the Generic and Biosimilar Medicines Association (GBMA) begins negotiations with government on the next strategic agreement, it has unveiled […]
MoreNews - MedTech & Diagnostics
Australia sets a new course for prostate cancer detection
Australia has become one of the first countries in the world to adopt a modern, evidence-based framework for the early […]
MoreNews - Pharmaceuticals
IVF success rates climb as ART sector faces major accreditation overhaul
Australians undergoing in vitro fertilisation (IVF) are now more likely to take home a baby than they were five years […]
More